{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhang Y"],"funding":["Health and Medical Research Fund Hong Kong","RGC Theme-based Research Scheme","National Natural Science Foundation of China","Research Grants Council of the Hong Kong Special Administrative Region","CUHK Research Startup Fund"],"pagination":["639-651"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12014897"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["74(4)"],"pubmed_abstract":["<h4>Background</h4>Transmembrane 6 superfamily member 2 (TM6SF2) has a protective role against metabolic dysfunction-associated steatotic liver disease (MASLD).<h4>Objective</h4>We aim to investigate the mechanistic role and therapeutic potential of hepatic TM6SF2 in MASLD-related hepatocellular carcinoma (HCC).<h4>Design</h4>Hepatocyte-specific <i>Tm6sf2</i> knockout (<i>Tm6sf2</i> <sup>∆hep</sup>) mice were fed with high-fat/high-cholesterol (HFHC) diet or diethylnitrosamine plus HFHC diet to induce MASLD-HCC. TM6SF2 function was also evaluated in orthotopic MASLD-HCC mice. Human MASLD-HCC specimens were included to evaluate clinical significance.<h4>Results</h4>TM6SF2 was downregulated in tumours compared with adjacent normal tissues from MASLD-HCC patients. Hepatocyte-specific <i>Tm6sf"],"journal":["Gut"],"pubmed_title":["Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy."],"pmcid":["PMC12014897"],"funding_grant_id":["FPU/2023/149","82272619","82222901","08191336","CUHK 14117422","82103355","T12-703/19-R","CUHK 14117123","07210097","CUHK 14119524"],"pubmed_authors":["Cheung AH","Xie M","Yu J","Lau HCH","Liu W","Man K","Liang C","Liu Y","Wen J","Zhang Y","Song Q","Zhang X","Song Y"],"additional_accession":[]},"is_claimable":false,"name":"Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy.","description":"<h4>Background</h4>Transmembrane 6 superfamily member 2 (TM6SF2) has a protective role against metabolic dysfunction-associated steatotic liver disease (MASLD).<h4>Objective</h4>We aim to investigate the mechanistic role and therapeutic potential of hepatic TM6SF2 in MASLD-related hepatocellular carcinoma (HCC).<h4>Design</h4>Hepatocyte-specific <i>Tm6sf2</i> knockout (<i>Tm6sf2</i> <sup>∆hep</sup>) mice were fed with high-fat/high-cholesterol (HFHC) diet or diethylnitrosamine plus HFHC diet to induce MASLD-HCC. TM6SF2 function was also evaluated in orthotopic MASLD-HCC mice. Human MASLD-HCC specimens were included to evaluate clinical significance.<h4>Results</h4>TM6SF2 was downregulated in tumours compared with adjacent normal tissues from MASLD-HCC patients. Hepatocyte-specific <i>Tm6sf","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-07-15T11:05:46.482Z","creation":"2025-07-03T03:04:39.275Z"},"accession":"S-EPMC12014897","cross_references":{"pubmed":["39667906"],"doi":["10.1136/gutjnl-2024-333154"]}}